Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 395-400

  Cao, Richard Yang ^a   St Amand, Tim ^a   Gräbner, Rolf ^b   Habenicht, Andreas J R ^b   Funk, Colin D ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Atherosclerosis; Inflammation; Leukotriene; Macrophage

Indexed keywords

3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; CALCIUM IONOPHORE; LEUKOTRIENE; LIPID; SCARLET RED;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CONTROLLED STUDY; DIET; DISEASE COURSE; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; GENE INACTIVATION; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING;

ANIMALS; APOLIPOPROTEINS E; ARACHIDONATE 5-LIPOXYGENASE; ATHEROSCLEROSIS; BICYCLO COMPOUNDS; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; LEUKOTRIENES; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; QUINOLINES;

EID: 62649157212     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.045     Document Type: Article

References (31)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 4597 (1983) 568-575
2. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
3. Tager A.M., Bromley S.K., Medoff B.D., et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 4 October (10) (2003) 982-990
4. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4 (2005) 664-672
5. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 (2003) 1238-1243
6. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
7. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
8. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126. [Erratum in: Circ Res 2002;91:e27. Corrected to Shi W]
9. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Freeman A., and Showell H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 March (3) (2002) 443-449
10. Subbarao K., Jala V.R., Mathis S., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 369-375
11. Zhao L., Moos M.P., Gräbner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973
12. Jawien J., Gajda M., Rudling M., et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 36 (2006) 141-146
13. Bäck M., Sultan A., Ovchinnikova O., and Hansson G.K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100 (2007) 946-949
14. Cipollone F., Mezzetti A., Fazia M.L., et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 25 (2005) 1665-1670
15. Qiu H., Gabrielsen A., Agardh H.E., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 103 (2006) 8161-8166
16. Zhou Y.J., Wang J.H., Li L., Yang H.W., Wen de L., and He Q.C. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability. Biochem Biophys Res Commun 363 (2007) 30-36
17. Bell R.L., Bouska J.B., Malo P.E., et al. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J Pharmacol Exp Ther 272 (1995) 724-731
18. Chen X.S., Sheller J.R., Johnson E.N., and Funk C.D. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372 (1994) 179-182
19. Sabirsh A., Bristulf J., Karlsson U., Owman C., and Haeggström J.Z. Non-specific effects of leukotriene synthesis inhibitors on HeLa cell physiology. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 431-440
20. Datta K., Biswal S.S., and Kehrer J.P. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J 340 (1999) 371-375
21. Ghazalpour A., Wang X., Lusis A.J., and Mehrabian M. Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice. Genetics 173 (2006) 943-951
22. Mehrabian M., Allayee H., Stockton J., et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 37 (2005) 1224-1233 [Erratum in: Nat Genet 2005;37:1381]
23. Schwartz S.M., Galis Z.S., Rosenfeld M.E., and Falk E. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol 27 (2007) 705-713
24. Jackson C.L., Bennett M.R., Biessen E.A., Johnson J.L., and Krams R. Assessment of unstable atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27 (2007) 714-720
25. Falk E., Schwartz S.M., Galis Z.S., and Rosenfeld M.E. Putative murine models of plaque rupture. Arterioscler Thromb Vasc Biol 27 (2007) 969-972
26. Zhao L., Cuff C.A., Moss E., et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 277 (2002) 35350-35356
27. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103 June (11) (1999) 1597-1604
28. Zhao L., and Funk C.D. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 14 July (5) (2004) 191-195
29. Jessup W., Darley-Usmar V., O'Leary V., and Bedwell S. 5-Lipoxygenase is not essential in macrophage-mediated oxidation of low-density lipoprotein. Biochem J 278 August (Pt 1) (1991) 163-169
30. Huang L., Zhao A., Wong F., et al. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 24 October (10) (2004) 1783-1788
31. Bäck M., Bu D.X., Bränström R., Sheikine Y., Yan Z.Q., and Hansson G.K. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 102 November (48) (2005) 17501-17506